drugset

drugset / Trial / NCT05587205

Safety and Tolerability of EO2002

NCT05587205 ↗

Phase 1 Recruiting 32 enrolled Asociación para Evitar la Ceguera en México Emmecell · collab

RandomizedSequentialDouble-blindTreatment

Summary

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Timeline

Start: 2022-08-30
Primary completion: 2026-10-06
Completion: 2026-10-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EO2002	Cell therapy	—	Other

Indications